+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rapastinel (Allergan) Drug Overview 2019

  • PDF Icon


  • 17 Pages
  • March 2019
  • Region: Global
  • Citeline
  • ID: 4846095
Drug Overview
Rapastinel (Allergan) is a synthetic tetrapeptide comprising of threonine–proline–proline–threonine that acts as a partial agonist at the glycine site of the NMDA receptor. This mechanism activates pathways involved with long-term plasticity and long-term depression, yielding pro-cognitive and antidepressant effects. Rapastinel has been developed specifically as an NMDA-targeting drug that can produce rapid-onset antidepressant activity without any psychotomimetic effects associated with other products like ketamine. As a peptide, rapastinel must be dosed intravenously to ensure its biological efficacy.

Rapastinel's Phase III treatment-resistant depression program washout is a significant blow for Allergan. The company has invested a great deal into its development of rapastinel with 10 Phase III pivotal trials in depression spanning treatment-resistant depression and major depressive disorder (MDD), as well as a Phase II trial for MDD with imminent risk of suicide. This has caused the company to miss out on the opportunity to break into the less saturated segment of the depression market.

Table of Contents

  • Drug Overview
  • Product Profiles
  • rapastinel: Depression

Table 1: Rapastinel drug profile
Table 2: Rapastinel completed Phase III trials in depression
Table 3: Rapastinel ongoing Phase III trials in depression
Table 4: Rapastinel Phase II data in depression
Table 5: Rapastinel ongoing Phase II trial in MDD at imminent risk of suicide
Table 6: Rapastinel for depression – SWOT analysis